Therefore, RNF43 is considered a valid target for anti-tumor, immunotherapeutic treatment [18,19] and the combination with DC vaccination is expected to synergistically increase the antitumor immunity targeting RNF43. This evidence concerns the gene RNF43 and neoplasm.